source
- BrainChild Bio secures $119M Series A to advance CAR-T therapy for deadly pediatric brain tumorBrainChild Bio announced a $119 million Series A financing round aimed at moving its CAR‑T programs for central nervous system cancers in children forward. The company’s lead candidate, BCB-276, w…
- Roivant's inhaled drug mosliciguat achieves positive Phase 2 results in interstitial lung diseaseRoivant Sciences reported that its inhaled candidate mosliciguat has successfully completed a Phase 2 trial in patients with interstitial lung disease. The study met its primary endpoint, showing a…